



Human Leukocyte Antigen (HLA) and Vaccines

Guest Editors:

**Prof. Dr. Apostolos P.
Georgopoulos**

Dr. Effie-Photini Tsilibary

Dr. Lisa M. James

Dr. Spyros Charonis

Deadline for manuscript
submissions:

closed (31 January 2021)

Message from the Guest Editors

Dear Colleagues,

The success of vaccines in preventing illness depends on our ability to make antibodies against the pathogen components contained in the vaccines; if antibodies cannot be made, the vaccine will not be effective. In this case, vaccine antigens persist with the possibility of causing cell damage either directly or via molecular mimicry and autoimmunity. Now, the mounting of antibodies against specific antigens critically depends on the individual's Human Leukocyte Antigen (HLA) Class 2 genetic makeup, which consists of more than six alleles (two for each of the DRB1, DQB1, and DPB1 genes, plus the occasional DRB3, DRB4, and DRB5 allele). This Special Issue will focus on this matter, which is of major medical and public health importance but hardly covered elsewhere.

Prof. Apostolos P. Georgopoulos

Dr. Effie-Photini Tsilibary

Dr. Lisa M. James

Dr. Spyros Charonis

Guest Editors





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia,
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus**, **SCIE (Web of Science)**, **PubMed**, **PMC**, **Embase**, **CAPus / SciFinder**, and **other databases**.

Journal Rank: JCR - Q1 (*Immunology*) / CiteScore - Q1 (*Pharmacology (medical)*)

Contact Us

Vaccines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com